ScholarX: LEE, JEONG WON

Detailed Information

LEE, JEONG WON (이정원)

Medicine (Medicine)

Research Area

Tel 02-3410-1382
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prognosis:21||Laparoscopy:17||Recurrence:16||Survival:15||Uterine cervical neoplasms:15||cervical cancer:12||Cervical cancer:11||Chemotherapy:10||Epithelial ovarian cancer:8||prognosis:7||Ovarian cancer:7||Ovarian Neoplasms:7||Endometrial cancer:6||Hysterectomy:6||Ovarian neoplasms:6||Gynecology:6||Ovarian neoplasm:5||Clear cell carcinoma:5||immunohistochemistry:5||Patientderived xenograft:5||Radiotherapy:5||siRNA:5||Borderline ovarian tumors:5||Ovarian carcinoma:5||Surgery:5||epithelial ovarian cancer:5||Cisplatin:4||Practice Guideline:4||Uterine Cervical Neoplasms:4||Magnetic resonance imaging:4||Adenocarcinoma:4||laparoscopy:4||Epithelial Ovarian Cancer:4||One port:3||Prognostic factor:3||Bevacizumab:3||surgery:3||survival:3||Singleport:3||Early cervical cancer:3||Pembrolizumab:3||Adjuvant radiotherapy:3||Lymph nodes:3||Concurrent chemoradiation:3||cervix neoplasms:3||Ovarian Cancer:3||cervical intraepithelial neoplasia:3||recurrence:3||Pregnancy:3||ovarian neoplasms:3||Endometrial neoplasms:3||Minimally invasive surgery:3||magnetic resonance imaging:3||Lynch syndrome:3||uterine cervical neoplasms:3||Laparoscopic surgery:3||Paclitaxel:3||Consensus:3||ovarian cancer:3||MicroRNA:3||Borderline ovarian tumor:3||Robotics:2||cMet:2||Bartholin glands:2||cancer:2||cancer immunotherapy:2||radical hysterectomy:2||Endometrial Neoplasms:2||SUVmax:2||carcinoma:2||Adjuvant chemotherapy:2||Male:2||Ovarian tumor:2||cisplatin:2||Galectin1:2||Overall survival:2||Ifosfamide:2||sphingosine kinase 1:2||Single port:2||combination therapy:2||Single port access:2||squamous cell:2||complication:2||Single port access (SPA):2||concurrent chemoradiation:2||concurrent chemoradiotherapy:2||targeted therapy:2||consolidation chemotherapy:2||Singleport access:2||therapeutic vaccine:2||DNA ploidy:2||Immune checkpoint inhibitors:2||Mesothelial cell:2||diseasefree survival:2||Immunohistochemistry:2||General Surgery:2||Benign metastasizing leiomyoma:2||endometrial cancer:2||uterus:2||Diagnosis:2||Stage:2||Subrenal capsule implantation:2||Papillomavirus Vaccines:2||Colorectal cancer:2||Geriatric Assessment:2||Cervical Cancer:2||PatientDerived Xenograft:2||Irradiation:2||hysterectomy:2||Cervical intraepithelial neoplasia:2||Molecular target:2||Topotecan:2||LESS:2||Toxicity:2||Drug Repurposing:2||Treatment:2||laparotomy:2||Gynecologic malignancy:2||Gynecologic neoplasms:2||HER2:2||Laparoscopic myomectomy:2||Myoma:2||FGF19:2||FGFR4:2||Precision medicine:2||Laparotomy:2||microarray:2||Uterine carcinosarcoma:2||Prognostic factors:2||HPV 16:2||Uterine fibroid:2||nanoformulation:2||neoadjuvant chemotherapy:2||Uterine leiomyoma:2||Uterine leiomyosarcoma:2||Leiomyoma:2||Leiomyosarcoma:2||Propensity ScoreMatching:2||HPV 18:2||Neoplasm staging:2||AZD4547:2||Cervix uteri:2||Dynamin 2:2||BRCA1:2||Liposome:2||Radiation:2||overall survival:2||Female:2||Local:2||adenoid cystic carcinoma:2||Histology:2||advanced ovarian cancer:2||Adjuvant chemoradiotherapy:2||Lung:2||Operative outcome:2||Choriocarcinoma:2||Elderly:2||Fluorodeoxyglucose F18:2||Outcome:2||Lymphatic metastasis:2||primary cytoreductive surgery:2||Risk factors:2||Cytoreductive surgery:2||Gene expression signature:1||Genes, BRCA1:1||Genes, BRCA2:1||Genetic Testing:1||Genetic profiling:1||Geriatric:1||Gestational trophoblastic disease:1||Gliomatosis peritonei:1||Glucose:1||Gold:1||Gonadotropin releasing hormone agonist:1||Grade 3 endometr:1||Gynecologic laparoscopy:1||Gynecological surgery:1||HER3:1||HIF2α:1||HIFU:1||HPV:1||HPV genotyping:1||HPV infection:1||Hemoglobins:1||High tesla magnetic resonance imaging:1||Highgrade serous carcinoma:1||Highintensity focused ultrasound ablation:1||Highthroughput screening:1||Histologic subtype:1||Hormone therapy:1||Human Papillomavirus:1||Human genome:1||Human papillomavirus (HPV):1||Human papillomavirus DNA tests:1||Human papillomavirus vaccine:1||Humanized:1||Hydrogel:1||Hypoxia:1||ID2:1||IV formula:1||Imageguided brachytherapy:1||Immune checkpoint inhibitor:1||Immunotherapy:1||In vivo:1||Inclusion:1||Indocyanine green:1||Interleukin31:1||International Federation of Gynecology and Obstetrics:1||Intraoperative Complications:1||Intraperitoneal Chemotherapy:1||Intraperitoneal bupivacaine:1||Intraperitoneal chemotherapy:1||Invasive implant:1||Keywords: FertilitySparing Surgery:1||Korean Gynecologic Oncology Group:1||Koreans:1||LGESS:1||La:1||Laminin:1||Laminin receptor:1||Laparoendoscopic singlesite surgery (LESS):1||Laparoscopic Surgery:1||Laparoscopicassisted vaginal hysterectomy:1||Laparoscopicassisted vaginal hysterectomy (LAVH):1||Laparoscopically assisted vaginal hysterectomy:1||Late complications:1||Learning curve:1||Length of stay:1||Lenvatinib:1||Less invasive surgery:1||Linalool:1||Linear regression:1||Liposomes:1||Locally advanced cervical carcinoma:1||Longterm survival:1||Losartan:1||Low anterior resection:1||Low malignant:1||Lymph:1||Lymph Node Excision:1||Lymph node:1||Lymphadenectomy:1||Lymphangitis carcinomatosa:1||Lymphocytes:1||Lymphovascular space invasion:1||MRI:1||Machine Learning:1||Machine learning:1||Malignant fibrous histiocytoma:1||MatchedPair Analysis:1||Matchedcase comparison:1||Melanoma:1||Mesenchymal tumor:1||Metastasectomy:1||Metastasis:1||Metastatic carcinoma:1||Metastatic tumors to the ovary:1||MiR200 family:1||MiTMAB:1||MicroRNA200c:1||Microarray:1||Microenvironment:1||Microinvasive carcinoma:1||Microsatellite instability:1||Middle Aged:1||Minimally invasive surgical procedure:1||Mismatch repair:1||Modified suture technique:1||Molecular ta:1||Molecular targeted therapy:1||Monoclonal:1||Monocyte:1||Monocytes:1||Mosapride:1||Mucinous cystadenoma:1||Mucinous tumors:1||Multivariate analysis:1||Mutation:1||Myomectomy:1||Myxoid:1||Myxoma:1||Nanosized drug delivery:1||Nanoparticle:1||Neoadjuvant therapy:1||Neoplasm Recurrence:1||Neoplasm invasiveness:1||Neoplasm metastasis:1||Neoplasm recurrence:1||Neutrophils:1||New classification:1||Nomograms:1||Nondiabetic:1||Nonhigh grade serous carcinoma:1||Nongestational:1||Normalsized Ovarian Carcinoma:1||Nuclear staining:1||OcTMAB:1||OctoPort:1||Olaparib:1||Omeprazole:1||Oncology:1||Operative time:1||Optimal cytoreduction:1||Optimal debulking surgery:1||Organoonpillar:1||Orthotopic model:1||Ovarian Epithelial Cancer:1||Ovarian epithelial cancer:1||Ovarian function:1||Ovarian germ cell cancer:1||Ovarian insufficiency:1||Ovarian metastasis:1||Ovarian metastatectomy:1||Ovarian serous carci:1||Ovarian teratoma:1||Ovarian transposition:1||Ovary:1||PARP Inhibitors:1||PARP inhibitor:1||PAUF:1||PET:1||PLGA Nanoparticle:1||PLGA nanoparticles:1||PLXDC1 siRNA:1||PNA:1||PNA microarray:1||POM121:1||Paclitaxelresistant:1||Pain:1||Paraaortic lymphadenectomy:1||Parametrial involvement:1||Parametrium:1||Pathology:1||Pathology Section:1||Patient safety:1||Patientderived organoid:1||Patientderived xenograft model:1||Patientderived xenograft model (PDX):1||Pediatrics:1||Penfluridol:1||Peritoneal carcinomatosis:1||Peritoneal tuberculosis:1||Pharmacogenomic analysis:1||Phosphatidylinositol 3kinase inhibitor:1||Placental site trophoblastic tumor:1||Platinum:1||Platinumfree interval:1||Platinumresistant:1||Port site metastasis:1||Positron Emission Tomography Computed Tomography:1||Positron emission tomography (PET):1||Positron emission tomography/computed tomography:1||Postoperative computed tomography:1||Practice Guidelines:1||Primary malignant melanoma:1||Primary peritoneal cancer:1||Primary repair:1||Prognostic model:1||Progression to invasive carcinoma:1||Propensity Score:1||Proton pump inhibitors:1||Pulmonary lymphangitic carcinomatosis:1||Pulmonary recruitment maneuver:1||RARβ:1||RNAseq:1||RNAi:1||RPPA:1||Radical Trachele:1||Radical hysterectomy:1||Radical surgery:1||Radical trachelectomy:1||Radioresistance:1||Ramosetron:1||Real world:1||Rectal:1||Recurrenc:1||Recurrent epithelial ovarian cancer:1||Resection margin:1||Residual disease:1||Residual tumor:1||Resistance:1||Resistance to KSP inhibition:1||Response rate:1||Retinoic acid receptors:1||Retroperitoneal space:1||Retrospective Studies:1||Retrospective studies:1||Revised FIGO staging:1||Risk factor for recurrence:1||Robotic surgery:1||Sphase:1||SPA:1||STAT3/CCL2:1||Safety:1||Salvage Therapy:1||Sarcoma, epithelioid:1||Secondary cytoreductive surgery:1||Selective Delivery:1||Selective progesterone receptor modulators:1||Self collection:1||Sensitivity:1||Serous cystadenoma:1||Sexuality and Gynecologic Cancer:1||Shoulder pain:1||Singleport access (SPA):1||Singleport access (SPA) surgery:1||Singleport myomectomy:1||Singlesite robotic surgery:1||Small interfering RNA:1||Sodium selenite:1||Specimen handling:1||Squamous cell carcinoma:1||Squamous cell carcinomarelated antigen:1||Squamous cell lesions:1||Stage I endometrial cancer:1||Stomach:1||Subtotal hysterectomy:1||Surgery, gynecological:1||Surgical Instruments:1||Survival Rate:1||Survival benefit:1||Symptom:1||Synchronous gynecologic tumor:1||TCGA:1||THZ1:1||TIP (paclitaxel, ifosfamide, cisplatin):1||TP53 mutations:1||Tetraarsenic hexoxide:1||Therapeutic target:1||Time management:1||Tolllike receptor 5:1||Total lesion glycolysis:1||Transient silencing effect:1||Treatment delay:1||Treatment interval:1||Treatment outcome:1||Tubulin inhibitor:1||Tumor growth:1||Tumor invasion:1||Tumor marker:1||TumorSpecific Antigen:1||Tumour heterogeneity:1||Ulipristal acetate (UPA):1||Urine specimen collection:1||Uterine Corpus Neoplasms:1||Uterine Diseases:1||Uterine Neoplasms:1||Uterine artery ligation:1||Uterine cancer:1||Uterine carcinoma:1||Uterine carcinosarcomas:1||Uterine cervical cancer:1||Uterine cervical neoplasm:1||Uterine cervix:1||Uterine neoplasm:1||Uterine papillary serous carcinomas:1||Uterus:1||VATPase:1||VAS score:1||Vacuolar protontranslocating ATPases:1||Vagina:1||Vaginal smear:1||Variant of unknown significance:1||Villoglandular adenocarcinoma:1||Vulva:1||Vulva neoplasms:1||Vulvar cancer:1||Waiting time:1||[F18]FDG PET/CT:1||adjuvant chemotherapy:1||adjuvant treatment:1||adoptive:1||age:1||ancestry:1||angiogenesis tumor therapy:1||animal model:1||anticancer agent:1||antigen delivery:1||antitumor efficacy:1||ascites:1||baseline lymphocyte count:1||belotecan:1||benign metastasizing leiomyoma:1||bioinformatics:1||biomarkers:1||body image:1||borderline ovarian tumor:1||borderline ovarian tumour:1||brain metastases:1||breast neoplasms:1||bulky cervical cancer:1||bulky cervical carcinoma:1||calpain 6 protein:1||cancer genome:1||cancer metastasis:1||carboplatin:1||caregivers:1||cervical carcinoma:1||cervical neoplasia:1||cervical ripening:1||cervical squamous cell carcinoma:1||chemoradioresistance:1||chemotherapy:1||clear cell adenocarcinoma:1||clinical trial:1||co:1||colposcopy:1||combination:1||complete resection:1||computed tomographic scan:1||conization:1||controlled drug release:1||cosmesis:1||cystectomy:1||cytoplasmic delivery:1||drug delivery:1||drug resistance:1||dynamic contrastenhanced magnetic resonance imaging:1||dynamin 2:1||endocytosis:1||epithelial ovarian carcinoma:1||fertilitysparing surgery:1||galectin3:1||gammaknife radiosurgery:1||gene expression profiling:1||gene signature:1||genes:1||germline mutation:1||gynecologic cancer:1||gynecology:1||health services needs and demand:1||hepatocyte growth factor:1||highdoserate brachytherapy:1||highintensity focused ultrasound:1||histologic subtype:1||histology:1||hormone therapy:1||human:1||human epidermal growth factor receptor:1||immune checkpoint inhibitor:1||immune response:1||immunotherapy:1||inclusion:1||intensitymodulated radiation therapy:1||laparoendoscop:1||laparoendoscopic singlesite:1||laparoscopic single site surgery:1||laparoscopically assisted vaginal hysterectomy:1||large ovarian tumor:1||leiomyoma:1||liposome:1||locally advanced cervical cancer:1||locally advanced cervical carcinoma:1||loss of heterozygosity:1||lymph node:1||lymph nodes:1||lymphadenectomy:1||lysyltRNA synthetase:1||mTOR:1||machine learning:1||matrix metalloproteinase2:1||mature cystic teratoma:1||metastasis:1||metastatic carcinoma:1||miR155:1||minimallyinvasive surgery:1||misoprostol:1||mitomycinC:1||mixed micelle:1||monocyte:1||mouse model:1||multitRNA synthetase complex:1||myoma:1||neoplasm invasiveness:1||neoplasms:1||nextgeneration sequencing:1||olaparib:1||optimal debulking:1||oral:1||outcome:1||ovarian cancer therapy:1||ovarian cancer treatment:1||ovarian highgrade serous carcinoma:1||ovarian neoplasm:1||ovarian ser:1||ovary of normal size:1||pSTAT3:1||p53:1||pNIB/PTX polymeric micelles:1||paclitaxel:1||pads:1||pap smear:1||papillary serous carcinoma:1||papillomavirus:1||paraaortic lymph node:1||patient care bundles:1||patientderived xenograft:1||pelvic insufficiency fracture:1||pelvic radiotherapy:1||perioperative care:1||personalized medicine:1||pharmacodynamics:1||pharmacokinetics:1||phase I:1||photothermal irradiation:1||platinum:1||platinum sensitivity:1||pmTOR:1||postoperative complications:1||prediction of optimal cytoreduction:1||predictive model:1||pregnancy:1||primary peritoneal carcinoma:1||progression:1||promoter hypermethylation:1||propensity score matching:1||protein expression:1||proteinprotein interaction:1||quality of life:1||quantitative trait loci:1||radiomics:1||reactive thrombocytosis:1||rechallenge:1||recombinant protein:1||recurrent cervical carcinoma:1||recurrent epithelial ovarian cancer:1||refractory cancer:1||regression:1||resectability:1||residual:1||retroperitoneal space:1||s gland:1||selfexamination:1||sigmoid colon perforation:1||single port access:1||singlenucleotide polymorphism:1||singleport access:1||siponimod:1||sphingosine1phosphate:1||splenectomy:1||splicing var:1||squamous cell carcinoma:1||squamous epithelium:1||stage IB1:1||sublingual:1||targeted delivery:1||the 2001 Bethesda System:1||therapeutic target:1||thermoresponsive drug delivery:1||tolllike receptor:1||toxicity:1||transcription factor:1||trastuzumab:1||treatment:1||tumor microenvironment:1||tumor regression:1||tumor suppressor genes:1||unilateral salpingooophorectomy:1||uterine cervical neoplasm:1||vaccination:1||vaginal:1||vincristine:1||vulvar cancer:1||<sup>18</sup>FFDG PET/CT:1||vulvar carcinoma:1||.:1||25hydroxyvitamin D:1||5AZA:1||67kDa laminin receptor:1||AGR2:1||AGTR1:1||AIMP2:1||ANXA2:1||ANXA4:1||ASCH:1||ASCUS:1||Ablation therapy:1||Accuracy:1||Activities of daily living:1||Adenocarcinoma in situ:1||Adenoid cystic carcinoma:1||Adnexal surgery:1||Advanced ovarian cancer:1||Advancedstage:1||Adverse effects:1||Aged:1||Anemia:1||Aneuploidy:1||Animal model:1||Annexin A4:1||Anticancer:1||Antibodies:1||Anticancer drug:1||Antineoplastic agents:1||Antitumor effect:1||Appendectomy:1||Appendix:1||Aprepitant:1||Ascites:1||Atopic dermatitis:1||Atypical glandular cells:1||Atypical squamous cells:1||Automated organospotter:1||Autophagy:1||B cell:1||BAF312:1||BR:1||BRCA1 gene:1||BRCA1 genes:1||BRCA2 gene:1||BRCA2 genes:1||BRD7:1||BSO:1||BVACC:1||Barbed suture:1||Bartholin&apos:1||Benign ovarian tu:1||Benzimidazole:1||Beta blocker:1||Biological markers:1||Biomechanics:1||Bladder dissection technique:1||Bone:1||Bone metastasis:1||Borderline tumor:1||Bulky earlystage cervical cancer:1||CA125:1||CA125 Antigen:1||CA125:1||CA199:1||CAIX:1||CO2 generation:1||CT:1||CTR1:1||CTR2:1||Calpain 6 protein:1||Cancer:1||Cancer Immunotherapy:1||Carbohydrate Antigen 125:1||Carboplatin:1||Carcinoma in situ:1||Casecontrol study:1||Cathepsin BSpecific doxorubicin prodrug nanoparticle:1||Cell Line Xenograft:1||Cell survival:1||Cervical neoplasm:1||Cervical neoplasms:1||Cervix:1||Cesarean section:1||Chemoradiation:1||Chemosensitivity:1||Chitosan nanoparticles:1||ClavienDind:1||Clear Cell Carcinoma:1||Cold coagulation:1||Colon:1||Combination therapy:1||Complication:1||Concurrent chemoradiotherapy:1||Conization:1||Conservative surgery:1||Consolidation chemotherapy:1||Contrast medium:1||Controlled release:1||Conventional:1||Cyclindependent kinase 7:1||Cystadenocarcinoma, Serous:1||Cystectomy:1||Cytoplasmic expression system:1||Cytoreduction surgical procedures:1||DASL assay:1||DD6:1||Dendritic Cell:1||Dexamethasone:1||Diagnostic Techniques and Procedures:1||Diagnostic imaging:1||Diphenylbutyl:1||Disease free survival:1||Double primary cancers:1||Doxorubicin:1||Drug Therapy:1||Drug resistance:1||Drug synergism:1||Drug therapy:1||Drugresistance:1||Dynasore:1||E:1||ENOTES:1||EGFR shRNA:1||ERCC1:1||East Asian Gynecologic Oncology Trial Group:1||Electrosurgical conization:1||Endocervix:1||Endometrial Cancer:1||Endometrial ca:1||Endometrial carcinoma:1||Endometrial neoplasm:1||Endometrial stromal sarcoma:1||Endometrioid Carcinoma:1||Endometrioid carcinoma:1||Endometriosis:1||Endometrium:1||Enhanced recovery after surgery (ERAS):1||Epithelial endometrial carcinomas:1||Epithelial ovarian tumors:1||Esomeprazole:1||Etoposide:1||F18 Sodiumfluoride (NaF):1||FIGO:1||FIGO stage:1||FIGO staging:1||FSH:1||FTY720:1||Fenbendazole:1||Fertility:1||Fertility Preservation:1||Fertility sparing:1||Fertilitysparing surgery:1||Flow cytometry:1||Fluorescence:1||Frozen section:1||Function:1||Functional dyspepsia:1||Functional tumour parameter:1||GOG criteria:1||Galectin3:1||Galectin7:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE